Research Funding Opportunities
EME funding opportunity 15/176 - Delirium
This is a call for science-driven applications to investigate the efficacy of interventions in the prevention or treatment of acute, time-limited delirium, including the use of novel or repurposed therapeutic agents. Applications that explore the mechanisms underlying the effects of the intervention or the delirium itself are encouraged. This call does not seek applications for the treatment of the specific conditions that may be the precipitating cause for the onset of delirium, e.g. the onset of an infection. Applications must concentrate on determining the clinical efficacy of interventions, but the inclusion of embedded hypothesis-driven mechanistic studies within the main clinical evaluation is strongly encouraged. Applications may investigate novel or repurposed interventions and technologies. Studies of incremental or minor improvements to existing technologies or discovery of new biomarkers are not within the remit of the EME programme. Projects must have a strong collaborative approach, involving at least two of academia, NHS and industry. The EME Programme is particularly keen to encourage collaboration with small and medium enterprises.
Please see the commissioning brief for details. The call closes at 1pm on 15 March 2016.
EME funding opportunity 15/177 - Graft versus host disease
This call is for proposals for research into the efficacy of interventions for the prevention, diagnosis or management of graft-versus-host disease. EME would be particularly supportive of multi-arm studies testing a range of novel treatments and the mechanisms underlying the effects of the intervention. Please see the commissioning brief and guidance notes for more information. The call closes at 1pm on 15 March 2016.
EME funding opportunity 15/178 - Use of cell therapies
Proposals are invited for studies into the use of cell therapies for the treatment of disease in adults and children. Proposals should describe translational cell therapy research that investigates the clinical efficacy of the treatment and has the potential to generate new knowledge, which could be used in the future clinical care of patients.
Proposals for use of cell therapies in neurological and ophthalmic conditions are particularly welcome.
Cell transplantation and cell rescue therapies for cancer treatment are not part of this call, unless using genetically modified cells.
Proposals that include embedded mechanistic studies within the main clinical evaluation are strongly encouraged.
Applicants should note that work on animals is not within the remit of the programme. Studies of incremental or minor improvements to existing technologies or discovery of new biomarkers are not within the remit of the EME programme. Projects must have a strong collaborative approach, involving at least two of academia, NHS and industry. The EME Programme is particularly keen to encourage collaboration with small and medium enterprises. Where appropriate, we encourage applicants to engage with the Cell Therapy Catapult as a source of expertise in this area.
EME funding opportunity 15/75 is now 15/179 - Mechanisms of action of health interventions
Proposals are sought for translational research into the underlying mechanisms of action of clinical and public health interventions. Studies must utilise patients or samples from current or completed NIHR-funded or NIHR-managed studies in any setting. Proposals will be accepted across a wide range of interventions, including behavioural, pharmaceutical, psychological, surgical and public health interventions. The research should be relevant to the intervention and outcomes proposed by the original study and add significantly to the scientific understanding of the mechanisms of action of the intervention.
The proposed research may involve the analysis or reanalysis of previously stored specimens or data, or the collection of new specimens or new data for additional analysis, provided it is obtained from study participants. Discovery of new biomarkers is not within the remit of the EME Programme.
Applicants will need to make a strong case for how a better understanding of the mechanisms of action will potentially contribute to the future use or development of the technology, future wealth creation and for the ultimate benefit of individual patients’ or the wider NHS.
Proposed research areas for 2015/2016 EME commissioned calls - updated 16 November 2015
Research in the following broad areas is likely to be commissioned during the next year, although the titles and timings may be subject to change. The individual commissioning briefs, which will be published when the calls open, will define the details of the calls.
EME researcher-led funding opportunity 15/180 - 16 November 2015
The EME Programme's researcher-led workstream is an ongoing research funding opportunity funded by the Medical Research Council. You are welcome to submit a preliminary application at any time; however, there will be three cut-off dates each year. The next deadline is 1pm on 15 March 2016. Further information is available from the EME website.
Proposed research areas for 2015 HTA commissioned calls - updated 11 November 2015
The HTA Programme is considering the following topic areas for future commissioned research. Please note that not all of these topics will ultimately be advertised, but if they are it is likely to be within the next 6 to 12 months. Please also note that topic areas and timings are subject to change. The individual commissioning briefs, which will be published when the call opens, will define the details of the call.
HTA funding opportunity 15/159 - Optimising nutrition during therapeutic hypothermia
The HTA seeks proposals answering the question "What is the optimum feeding strategy for newborns with hypoxic ischaemic encephalopathy during and after therapeutic hypothermia?" Therapeutic hypothermia is now the accepted standard practice for treating term babies that have suffered a hypoxic brain injury (a lack of oxygen) at birth. During this process the infant is cooled to between 33 and 35oC as soon as the diagnosis is confirmed and is kept cooled for approximately 72 hours. This is to help prevent further neurological damage and conditions that can result from this, such as cerebral palsy. There are clear protocols in place for how to cool babies, but what is as yet undetermined is how best to feed babies during and after therapeutic hypothermia.
Feeding strategies currently used during hypothermia include nil by mouth; providing minimal or “priming” amounts (trophic feeding) of expressed breast milk directly to the stomach (enteral feeding) via a nasogastric tube; or providing all nutrition intravenously (total parenteral nutrition) until the baby has been warmed up. These differences in practice are mainly due to concerns about the safety of enteral feeding following therapeutic hypothermia because of a possible compromise in intestinal perfusion, risk of necrotising enterocolitis and gastrointestinal tract impairment. A cohort study is therefore proposed to try and determine if there are any discernible differences in neonatal outcomes in babies fed in these different ways and inform the need for future research.
HTA funding opportunity 15/158 - Selective gut decontamination in critically ill children
The HTA seeks proposals answering the question whether it is feasible to conduct a study of selective gut decontamination in critically ill children in paediatric intensive care. Hospital-acquired (nosocomial) infections, in particular respiratory tract infections (such as pneumonia), are common in patients treated in intensive care units (ICU) and are associated with considerable mortality and morbidity. Infections in ICU patients are most frequently caused by potentially pathogenic microorganisms carried in the throat and gut, present either on ICU admission or acquired during the ICU stay.
One strategy that has been found to be effective in reducing mortality from such infections in adults is selective decontamination of the digestive tract (SDD). SDD is an antibiotic prophylaxis strategy consisting of oropharyngeal (mouth) and gastric (stomach) application of specific non-absorbable antibiotics to reduce/eradicate the presence of harmful microorganisms only, as opposed to using broad spectrum antibiotics that can disrupt the gut’s natural flora. The most recent ecological study conducted in adults found that the continuous use of SDD was actually associated with a reduction in antibiotic resistance rates. Evidence of the use of SDD in children admitted to paediatric ICU, however, is limited. Mortality rates in PICU are typically very low and previous studies have not indicated a benefit in terms of mortality but do indicate that it may be successful at reducing ventilator-acquired pneumonia, which itself is associated with an increased duration of mechanical ventilation, length of hospital stay, cost of admission and morbidity and mortality. Fears remain, however, of the risk of antibiotic resistance. Therefore, the Paediatric Intensive Care Society has highlighted that this is an important area for further research before such a strategy can be recommended. Given that this intervention is not currently used in UK PICUs, a feasibility and randomised pilot trial is proposed in the first instance to determine whether it will be possible to deliver a substantive trial.
HTA funding opportunity 15/151 - Pharmacological management of diarrhoea in patients with ulcerative colitis
The HTA seeks proposals answering the question of which pharmacological interventions are most effective, and most acceptable to patients, in the treatment of diarrhoea in ulcerative colitis (UC). UC is a form of inflammatory bowel disease which affects the colon. There may be signs of disease in the skin, joints and other areas apart from the gut. Diarrhoea is a common problem in sufferers; treatments are aimed primarily at inducing and maintaining disease remission rather than at diarrhoea symptoms directly. Residual problems of diarrhoea and urgency during periods of remission can still affect some patients but the best treatments for these troublesome symptoms, which can have both significant physical and emotional impact, is unclear. There is a significant lack of evidence on which pharmacological interventions are most effective or safe, so well designed and appropriately controlled clinical trials are needed. This is particularly important since some treatments (e.g. loperamide) are available off the shelf for patients and the potential risks and benefits are not clear in this patient group.
Crick Clinical Research Fellows Programme
HTA researcher-led funding opportunities - updated 5 November 2015
The researcher-led workstream welcomes proposals on topics or research questions identified by researchers within the programme’s remit. The HTA can verify this for you if you complete and submit a remit check form. The deadlines for the next rounds are Friday 4 December 2015, Friday 8 April 2016, Wednesday 10 August 2016 and Wednesday 30 November 2016. Details can be found on the HTA website. Please note that the guidance notes have been updated since the researcher-led call launch in September 2014. Make sure you use the latest version as there have been changes to the advice on technical use of the form and costings for studies.
Core Research Essay Prize 2016
Core is offering a £1,000 award for the best essay based on gastroenterology or hepatology research undertaken by a clinical or basic science researcher during their MD or PhD. The work must be the subject of at least one abstract submitted for presentation at the 2016 British Society of Gastroenterology Annual Meeting in Liverpool. Further information and the application form are available to download. The closing date is 4 March 2016.
Dr Falk Pharma / Core Awards 2016
The Dr Falk/Core awards recognise those who bring new knowledge and insight to the field of gastroenterology and hepatology. For those committed to furthering research or patient care, the 2016 awards are an opportunity to achieve national recognition as well as the financial support to take your career further.
This year's prizes consist of the following:
- A £1000 prize for the best essay on gastroenterology research personally undertaken by medical students who were on an intercalated BSc/MRes/MSc/MPH/MBPhD* course during the previous academic year (2014/2015) - download the application
- Four £1500 bursaries for medical students taking full-time science degrees (BSc/MRes/MSc/MPH/MBPhD*) focusing on gastrointestinal or liver-related disease in the current academic year (2015/2016) - download the application
- Two £2500 bursaries to support research for F1/F2 doctors who are undertaking research in an area relevant to gastroenterology - download the application
- A £1,000 award for primary and secondary care nurses for initiatives that have advanced patient care - download the application.
*PhD students should note that they may apply for a bursary only once during their three-year studentship and that they may apply for the essay prize when their PhD has been completed.
The application deadline is 17:00 on Friday 4 March 2016. Applications received after this time will not be considered.
Graham Bull Prize 2016
The Graham Bull prize was established in 1988 in honour of Sir Graham Bull, who was the first director of the Clinical Research Centre at Northwick Park. A trust for the Graham Bull Prize was set up to provide money for young research workers under the age of 45 who feel that they have made a major contribution to clinical science. The prize as designed by the trust is specifically for an application and not for nomination of individuals. The work can cover a wide range of expertise, such as molecular and cellular biology, imaging technology, psychiatry, or health sciences. The award is open to RCP members and fellows who must apply for their own work to be considered. The sum of £1,000 is offered on a competitive basis each year.
The winner of this prize will also be invited to deliver the Goulstonian Lecture, an annual lecture endowed in 1635 by Mrs Ellen Goulston in memory of her husband, Dr Theodore Goulston FRCP.
Researchers must be under the age of 45 years on 1 April 2016, and must be a member or fellow of RCP London.
How to apply
Clinical Research Training Fellowship
Coeliac UK has joined forces with the Medical Research Council to offer jointly funded Clinical Research Training Fellowships. Our aim is to build a funding programme that will support the creation of the next generation of researchers focusing on coeliac disease. We wish to attract clinically active professionals within the UK and encourage them to embark on an early career in coeliac disease.
For further information and to submit an application, please visit the Medical Research Council. The Medical Research Council provides the most up to date list of deadlines, including interview and take up dates.
The Crohn's in Childhood Research Association offers the following bursaries:
Bursary grants of up to £400 (up to a total amount of £5,000pa) to enable UK based young doctors still in training/nurses/final year medical students and similar persons with an interest in the area of Crohn's and colitis (IBD) to support attendance at national, international scientific/educational congresses and if considered appropriate IBD related training courses. Also a £1000 annual bursary for travel/registration at national and international meetings for doctors in training to become paediatric gastroenterologists.
Application forms and further information can be obtained from the CICRA website: http://www.cicra.org/what-we-do/research/grant-applications
MRC Biochemical Catalyst: Developmental Pathway Funding Scheme - reminder
The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including “repurposing” of existing therapies. DPFS is an ongoing scheme, with outline deadlines every 4 months. The next deadline for outline proposals is 4pm on 2 December 2015. Please note that full submissions to DPFS are by invitation only; submission to the full call is contingent upon prior submission and shortlisting of an outline proposal. Further details are available from the MRC website.
Pump prime funding for initial feasibility studies
NIHR Enteric HTC aims to identify and address unmet clinical need in the diagnosis and management of disorders of the gastrointestinal tract and bowel function. The HTC seeks new ideas for medical device innovations and offers the opportunity to apply to NIHR Enteric HTC for pump prime funding for initial feasibility studies on potential new medical technologies within the field of digestive diseases and GI surgery.
- Further information[ 33 kb ]
MRC Public Health Intervention Development Scheme (PHIND)
The Public Health Intervention Development scheme (PHIND) is a new MRC funding scheme designed specifically to provide support for early phase development of public health interventions. This rapid response funding scheme is aimed at improving the initial evidence on which the development and evaluation of public health interventions are based. Studies should address an important UK or global public health issue and offer an innovative approach to intervention development or applying an existing intervention in a new setting.
The scheme's remit ranges from primary research developing and designing the intervention to feasibility studies, encompassing:
- developing theory
- modelling process and outcomes
- assessing feasibility
Systematic reviews, meta analyses and pilot studies are outside the remit of the PHIND scheme. Applicants can apply for up to £150K for a maximum of 18 months and the scheme will operate three times a year. For further information, please see the MRC website.